




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/52, 1/21, 15/55 // (C12N 1/21, C12R 1:19)		A1	(11) International Publication Number: WO 98/07869 (43) International Publication Date: 26 February 1998 (26.02.98)
(21) International Application Number: PCT/KR97/00152 (22) International Filing Date: 9 August 1997 (09.08.97)		(81) Designated States: AU, CA, CN, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 1996/33998 16 August 1996 (16.08.96) KR 1996/63255 9 December 1996 (09.12.96) KR		Published <i>With international search report</i> <i>With an indication in relation to a deposited microorganism</i> <i>furnished under Rule 13bis separately from the description.</i> <i>Date of receipt by the International Bureau:</i> 09 September 1997 (09.09.97)	
(71) Applicant: DONG WHA PHARM. IND. CO., LTD. [KR/KR], 5, Soonwha-dong, Joong-ku, Seoul 100-130 (KR).			
(72) Inventors: YOON, Sung, June; 1420-11, Shilim 5-dong, Kwanak-ku, Seoul 151-015 (KR). KIM, Jong, Woo; 1029, Bisan 3-dong, Dongan-ku, Anyang-si, Kyoungki-do 431-053 (KR). HUH, Yong; 368-508, Toegae Apt., Kumjeong-dong, Kunpo-si, Kyoungki-do 435-050 (KR). RHO, Yune, Mo; 1-1003, Mijoo Apt., Banpo 2-dong, Seocho-ku, Seoul 137- 042 (KR). JUNG, Gu, Hung; 239-1, Bongcheon 7-dong, Kwanak-ku, Seoul 151-057 (KR).			
(74) Agent: LEE, Won, Hee; Chunwoo Building, 5th floor, 736, Yoksam-dong, Kangnam-ku, Seoul 135-080 (KR).			

(54) Title: HBV POLYMERASE, RNase H ENZYME DERIVED FROM HBV POLYMERASE, PROCESSES FOR PREPARATION AND USES FOR SCREENING ANTIVIRAL AGENTS THEREOF



(57) Abstract

The present invention relates to hepatitis B virus (hereinafter it refers to HBV) polymerase containing a histidine tag, RNase H enzyme derived from HBV polymerase and processes for preparation thereof. More particularly, the present invention relates to recombinant HBV polymerase, its RNase H domain with enzyme activity, expression vectors producing the enzymes in *E. coli* and processes for preparing the HBV polymerase and the RNase H enzyme which can be easily purified due to their histidine tags. The present invention relates to uses of the HBV polymerase and the RNase H enzyme for screening antiviral agents.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroun	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HBV polymerase, RNase H enzyme derived from HBV polymerase, processes for preparation and uses for screening antiviral agents thereof

5

Field of the Invention

The present invention relates to hepatitis B virus (hereinafter it refers to HBV) polymerase containing a histidine tag, RNase H enzyme derived from HBV polymerase and processes for preparation thereof.

More particularly, the present invention relates to recombinant HBV polymerase, its RNase H domain with enzyme activity, expression vectors producing the enzymes in *E. coli* and processes for preparing the HBV polymerase and the RNase H enzyme which can be easily purified due to their histidine tags.

And the present invention relates to uses of the HBV polymerase and the RNase H enzyme for screening antiviral agents.

HBV is the main virus among hepatitis viruses, which infects more than 300 million people worldwide. HBV causes acute or chronic hepatitis, which results in liver cirrhosis or liver cancer (Tiollais and Buenda, Scientific American, 264 : 48-54, 1991 ; Blumberg, B. S.,

research, F. V. Chisari, ed., New York, Mason publishing, 1984). Because of molecular characteristics of HBV and its close relation with liver diseases, various researches about HBV have been accomplished.

5

HBV is a DNA virus, a member of the hepadnaviridae family, which has a spherical structure composed of nucleocapsid and core. HBV genome is a partially double stranded DNA of only 3.2 kb size, which is not a circular form. In detail, HBV genome is composed of four overlapped genes that are the polymerase (P) gene, the surface protein (HBsAg; S, pre-S1, pre-S2) gene, the core protein (HBcAg; pre-C, C) gene and X protein (HBx) gene. Among these genes, X protein gene encodes regulatory protein, and the other genes encode structural proteins of HBV. The polymerase gene occupies 80% of the total genome and encodes 94 KD-sized protein composed of 845 amino acids.

20 HBV infects hepatic cells by the process described below. The specific receptor of the hepatic cell recognizes the surface protein on the surface of the virion particle and binds with them so as to draw the virion into the hepatic cell. Then HBV polymerase synthesizes the single-stranded part of partially double-stranded DNA in order to obtain complete HBV

genome. And the HBV genome of 3.2kb size is transcribed with cellular RNA polymerase to produce pre-genomic mRNA of about 3.5kb, core protein (C) mRNA, surface protein mRNA and X protein mRNA. Viral proteins are translated from these mRNAs. Specially HBV polymerase synthesizes an RNA intermediate with its reverse transcriptase activity so as to provide a template for the DNA genome and make a replicasome structure with the pre-genomic mRNA, the core protein and the like, which is called encapsidation process. The HBV genome can be encapsidated easily since 3'-terminus of the polymerase containing continuous glutamic acid residues has affinity with nucleic acids. The above RNA intermediate in the replicasome serves as a template for minus strand DNA synthesis and then the full-length minus strand serves as a template for plus strand DNA synthesis by DNA-dependent DNA polymerase (DDDP) activity of the polymerase so as to make total pre-genomic mRNAs finally. By repeating the above process, more than 200-300 copies of the genomic DNA is maintained in pool and the viral proteins mentioned above are expressed (Tiollais and Buenda, Scientific American, 264: 48-54, 1991 ; Ganem, D. and Varmus, H. E., Annu. Rev. Biochem., 56 : 651-693, 1987).

Interestingly, HBV replicates its genome by using the RNA intermediate and reverse transcription even though it

is a DNA virus. It is known that retrovirus exploits the reverse transcription to replicate its genome. Particularly, the polymerase of retrovirus is reported to be a multifunctional enzyme which shows DNA-dependent DNA
5 polymerase activity, reverse transcriptase activity, and RNase H activity. It is remarkable that HBV polymerase contains a series of functions necessary for the replication of virus genome. Namely, the following functions : (i) protein primer, (ii) RNA-dependent DNA
10 polymerase (RT), (iii) DNA-dependent DNA polymerase (DDDP), (iv) RNase H activity consist in one polypeptide. The reverse transcriptase activity of HBV polymerase was first reported by Kaplan et al., and has been exploited to elucidate the mechanism of HBV replication.

15 As mentioned above, a reverse transcriptase has an active RNase H domain commonly which recognizes RNA / DNA complex and hydrolyzes only the RNA strand selectively. The RNase H activity is indispensable to the reverse transcription, since the reverse transcriptase can
20 replicate DNA continuously only after RNA intermediate is hydrolyzed by the RNase H activity. Although RNase H enzyme is known as a domain of the reverse transcriptase recently, RNase H enzyme was first discovered in the calf thymus by Hausen and Stein, and has been reported from
25 various prokaryotes and eukaryotes (Stein, Hans and Hausen, P., Science, 166 : 393-395, 1969).

Generally speaking, an active RNase H domain of HBV polymerase is localized within its C-terminus. The amino acid sequence and nucleotide sequence of the polymerase were reported to be very similar to those of the polymerase of Moloney murine Leukemia Virus. In addition, an active RNase H domain of HBV polymerase was known to synthesize a plus strand primer which can be derived from the pre-genomic RNA putatively. Particularly, it was identified by performing mutagenesis that the conserved sequence in the RNase H enzyme was necessary for viral proliferation. In addition, the RNase H domain plays a role to synthesize a minus strand DNA as well as the plus strand DNA and to perform RNA packaging, which is identified by mutating the RNase H domain of duck HBV polymerase. But it is reported recently that duck HBV polymerase can not recognize binding region ϵ within the pre-genomic RNA of human HBV.

Therefore, human HBV polymerase and its RNase H domain should be studied directly in addition to indirect researches by utilizing duck HBV polymerase in order to elucidate human HBV and the mechanism of its polymerase. Hitherto, the surface protein and the X protein which is necessary for the development of vaccines and for the regulation of transcription in proceeding liver cancer respectively has been studied actively. However, HBV

polymerase has seldom been exploited although it can be used to develop antiviral agents. Because HBV polymerase is difficult to be separated from virus particle and to obtain sufficient amounts, especially as an active form

5 (Radziwill, G. et al., Virology, 163 : 123-132, 1988). Presently, in order to develop novel therapeutical agents for hepatitis, cell lines infected with HBV have been used for screening antiviral agents. However, effective therapeutical agents has not been yet developed, since it

10 takes longer time and costs more for a screening method using cell lines than for screening methods using HBV polymerase or its RNase H enzyme.

Recently in order to elucidate HBV, HBV polymerase

15 and its RNase H domain have been studied as described above. Particularly researches for the mass production of above enzymes have been attempted by using recombinant DNA technology. The inventors of the present invention have produced a recombinant HBV polymerase which is

20 expressed from *E. coli* transformant, measured its enzyme activity and filed a patent application thereof (Korean Patent Application 94-3918). The recombinant HBV polymerase was produced in *E. coli* as a form of fusion protein with maltose binding protein (MBP), and can be

25 easily purified by MBP affinity column chromatography. But active HBV polymerase is difficult to be obtained

massively because the polymerase can be degraded at the C-terminus and has low purity.

Foreign proteins can be obtained massively by inserting a histidine tag into the proteins by recombinant DNA technology. The nucleotide sequences encoding histidine tag is inserted into the 5'-terminus or 3'-terminus of the gene, and the histidine-tag prevents degradation of the recombinant protein so as to prepare stable enzyme. In addition, the highly active recombinant protein can be purified easily by using histidine tag affinity column as a metal chelating affinity column.

In order to develop effective therapeutical agents, HBV polymerase and its RNase H enzyme have been produced by processes of the present invention. The inventors constructed expression vectors containing HBV polymerase gene with nucleotide sequences encoding a histidine tag at the C-terminus of the recombinant protein and expression vectors containing RNase H domain gene which is derived from the 3'-terminus of the HBV polymerase gene. In addition, HBV polymerase and its RNase H domain have been produced as forms of fusion protein massively in *E. coli* by using the expression vectors and purified easily by using amylose column and histidine tag affinity

column. Thus highly active and stable HBV polymerase and its RNase H enzyme which are not degraded can be prepared. Furthermore, the inventors have developed novel screening methods for antiviral agents by using the
5 HBV polymerase and its RNase H domain of the present invention.

Summary of The Invention

10 The object of the present invention is to provide HBV polymerase containing a histidine tag, RNase H enzyme derived from HBV polymerase and processes for preparation thereof.

Particularly, the present invention provides
15 expression vectors containing the HBV polymerase gene and process for preparing the HBV polymerase in *Escherichia coli*.

In addition, the present invention provides expression vectors containing RNase H gene derived from
20 human HBV polymerase gene and process for preparing the RNase H enzyme in *Escherichia coli*.

And, the object of the present invention is to provide uses of the HBV polymerase and the RNase H enzyme for screening antiviral agents.

25 Particularly, the present invention provides methods for screening inhibitors of the HBV polymerase and the

RNase H enzyme.

Brief Description of the Drawings

5 Fig. 1 depicts a strategy for constructing the expression vector pMPH which produces the HBV polymerase containing a histidine tag.

 Fig. 2 depicts the HBV polymerase which has been produced and purified from *E. coli* NM 522 /pMPH
10 transformant by SDS-polyacrylamide gel electrophoresis.

 lane 1 : the HBV polymerase purified primarily by amylose column

 lane 2 : the HBV polymerase purified secondarily by histidine tag affinity column

15 Fig. 3 depicts a strategy for constructing the expression vector pMPRL which produces the RNase H enzyme derived from the HBV polymerase.

 Fig. 4 depicts a strategy for constructing the expression vector pMRH which produces the active
20 histidine-tagged RNase H enzyme derived from human HBV polymerase.

 Fig. 5 depicts the RNase H enzyme which has been produced and purified from the *E. coli* NM 522/pMRH by SDS-polyacrylamide gel electrophoresis.

25 lane 1 : standard marker (molecular weight is 97, 68, 43 and 29 KD respectively);

lane 2 : crude extract of *E. coli* transformant

lane 3 : the RNase H enzyme purified primarily by amylose column

lane 4 : the RNase H enzyme purified secondarily by
5 histidine tag affinity column

Fig. 6 depicts the RNase H enzyme which has been produced and purified from the *E. coli* NM522 /pMRH transformant by western blotting analysis.

A : a result using anti-maltose binding protein

10 B : a result using antibody against histidine tag
(^{MRGS}HIS)

Each lane is explained on the above Fig. 5

Fig. 7 depicts RNA / DNA complex used in assaying the RNase H activity of the present invention.

15 Fig. 8 represents the results comparing RNase H activities of following samples, (i) maltose binding protein, (ii) crude extract of the *E. coli* transformant cultured, (iii) the RNase H expressed and purified by using the expression vector pMPRL and amylose column,
20 (iv) the RNase H expressed and purified by using the expression vector pMRH and amylose column, histidine affinity column, (v) reverse transcriptase of Moloney murine Leukemia Virus

Fig. 9 represents the increase of the RNase H
25 activity according to the amount of the RNase H enzyme.

Fig. 10 represents the increase of the RNase H

activity according to the reaction period of the RNase H enzyme.

Fig. 11 represents the variation of the RNase H activity according to the reaction temperature.

5 Fig. 12 represents the variation of the RNase H activity according to the pH of the reaction solution.

Fig. 13 represents the variation of the RNase H activity according to the concentration of potassium chloride.

10 Fig. 14 represents the variation of the RNase H activity according to the concentration of magnesium ion.

Fig. 15 represents the variation of the RNase H activity according to the concentration of manganese ion.

15 Detailed Description of The Preferred Embodiments

The present invention provides HBV polymerase containing a histidine tag which is prepared by inserting nucleotide sequences of the histidine tag into the end of
20 HBV polymerase gene.

Since the HBV polymerase containing a histidine tag is stable and can be easily purified, its activity of reverse transcriptase and the like can be measured properly. By using site-specific insertion mutagenesis
25 and so on, nucleotide sequences of histidine tag can be inserted into 5'-terminus or 3'-terminus of the HBV

polymerase gene.

Particularly, the present invention has exploited the expression vector already established (Korean Patent Application 94-3918) which produces the HBV polymerase fused with maltose binding protein (MBP). And nucleotide
5 fused with maltose binding protein (MBP). And nucleotide sequence of 6 histidine residues is inserted into the 3'-terminus of HBV polymerase gene. Especially since the histidine codons are inserted continuously right before the stop codon, the open reading frame (ORF) of the HBV
10 polymerase gene is setted exactly. The histidine tag can be inserted into the C-terminus of the polymerase, which maintains the enzyme activity. As a result, the expression vector pMPH has been constructed, which can produce the HBV polymerase fused with maltose binding
15 protein and histidine tag (see Fig. 1).

To express the recombinant polymerase, microorganism is transformed with the expression vector pMPH so as to prepare transformant. The microorganism mentioned above contains all kinds of *Escherichia coli* which is suitable
20 for the expression of recombinant proteins

Particularly, *E. coli* NM522 strain was transformed with the expression vector pMPH and the transformant has been deposited with Korean Culture Center of Microorganism, Seoul, Korea, on July 19, 1996 (Accession
25 number : KCCM-10084).

The present invention provides a process for preparing the recombinant HBV polymerase massively. *E. coli* transformant containing the expression vector is induced to express the recombinant protein and disrupted to obtain crude extract, then the HBV polymerase is purified by using histidine tag affinity column chromatography and other chromatographies.

Precisely, since the *E. coli* transformant containing the expression vector pMPH produces the recombinant HBV polymerase fused with MBP at the N-terminus, the HBV polymerase is purified as a form of fusion protein by using amylose resin column. And the histidine tagged polymerase only can be obtained separating MBP by treating protease factor Xa and the like.

In addition, the histidine tagged HBV polymerase is purified highly and conveniently by performing the metal chelating affinity column as histidine tag affinity column. The histidine tag maintains enzyme activity of the recombinant HBV polymerase during the purification process since it prevents protein degradation as well as facilitates the purification process of the HBV polymerase.

The present invention provides the RNase H enzyme derived from HBV polymerase.

Since human HBV polymerase has a RNase H domain with

enzyme activity at the N-terminus, the RNase H domain of the present invention is prepared by inserting 3'-terminus of the HBV polymerase gene into a expression vector and inducing *E. coli* transformant.

5

The present invention provides expression vectors which produces the RNase H enzyme fused with MBP to prepare the RNase H enzyme derived from the HBV polymerase.

10 Precisely, the RNase H subdomain gene of the HBV polymerase can be obtained by performing polymerase chain reaction (PCR) which utilizes oligonucleotides of SEQ ID. NO: 2 and SEQ ID. NO: 3 as primers (see Sequence Listing) and the expression vecor pMPLX already established as a
15 template. The expression vector pMPLX can produce the HBV polymerase as a form fused with MBP (Korean Patent Application 94-3918). RNase H enzyme gene obtained above has been inserted into the plasmid vector pMAL-c2 to construct the expression vector pMPRL (see Fig. 3).

20 Particularly, *E. coli* NM522 strain was transformed with the expression vector pMRH and the transformant has been deposited with Korean Culture Center of Microorganism, Seoul, Korea, on Nov. 29, 1996 (Accession number : KCCM-10092).

25

In addition, the present invention provides

expression vectors which produces RNase H enzyme fused with MBP and histidine tag in order to prepare the RNase H enzyme derived from the HBV polymerase.

Precisely, the gene fragment of the HBV polymerase containing nucleotide sequences of histidine tag is obtained from the expression vector pMPH and inserted into the expression vector pMPRL to construct the expression vector pMRH (see Fig. 4).

Particularly, *E. coli* NM522 strain was transformed with the expression vector pMRH and the transformant has been deposited with Korean Culture Center of Microorganism, Seoul, Korea, on Nov. 11, 1996 (Accession number : KCCM-10091).

The present invention provides a process for preparing the RNase H enzyme derived from the HBV polymerase by utilizing the expression vectors and the transformants describe above.

Precisely in order to purify the RNase H domain of the HBV polymerase, *E. coli* transformant containing the expression vector is induced for the protein expression, disrupted to obtain crude extracts, then RNase H enzyme as a form of fusion protein is purified by using amylose resin and maltose-containing buffer. And the histidine tagged RNase H enzyme only can be obtained separating MBP by treating protease factor Xa and the like. And the

histidine tagged RNase H enzyme is purified higherly by performing histidine tag affinity column chromatography as the same process described above.

5 Molecular weights and purity of the HBV polymerase and the RNase H enzyme purified above have been determined by using SDS-polyacrylamide gel electrophoresis and western blotting. As a result, the HBV polymerase and the RNase H enzyme of the present
10 invention is identified to be intact forms which has not been degraded (see Fig.2, Fig. 5 and Fig. 6).

 And reverse transcriptase activity in the HBV polymerase of the present invention has been examined.
15 As a result, the recombinant polymerase with MBP and histidine tag has shown higher activity of reverse transcriptase than the polymerase without histidine tag. In detail, activities of DNA dependent DNA polymerase (DDDP) and RNA dependent DNA polymerase (RDDP) have been
20 19 times higher in histidine tagged form than those in intact form (see Table 1).

 Precisely, in order to investigate RNA degradation by the RNase H activity, RNA / DNA complex is used as a substrate for the enzyme reaction. As a DNA template for
25 preparing RNA / DNA complex, the plasmid pBS-oligo derived from the plamid pBS is selected, digested within

restriction site *Sma*I, 102 nucleotides downstream from T7 promoter and then in vitro translation has been performed by using T7 RNA polymerase, radioactive nucleotides and so on. And RNA of 102 nucleotides is obtained by using
5 QIAquick nucleotide removal kit, QIAGEN and synthetic DNA oligonucleotide (43-mer) of SEQ ID NO: 4 is added to prepare RNA / DNA complex which is shown in Fig. 7 (see Sequence Listing).

10 In order to measure the RNase H enzyme activity, radioactive RNA / DNA complex is reacted with the RNase H enzyme and the radioactivity in the supernatant of the reaction mixture is measured by using scintillation cocktail and the like. At that time maltose binding
15 protein as a contrast sample, crude extract fraction, commercially available reverse transcriptase of Moloney murine Leukemia Virus as a comparative sample and so on are utilized. As a result, RNase H enzyme of the present invention is more active than that of reverse
20 transcriptase of Moloney murine Leukemia Virus, approximately 90% activity (see Fig.8).

In order to examine the enzymatic properties of the RNase H domain, the RNase H activity is measured in various reaction conditions by using proper buffers and
25 radioactive RNA / DNA complex.

As results, the enzyme activity of the RNase H domain

increases according to the enzyme amount (see Fig. 9) and takes about 3 hours of the reaction period to be shown (see Fig. 10). And preferably the temperature range is 32-42°C for the enzymatic reaction (see Fig. 11) and pH range is broad comparatively such as 7.5-8.8 (see Fig. 12). And preferably the reaction mixture for the enzymatic reaction should have 20-100mM range of KCl concentration (see Fig. 13), 4-8mM range of magnesium concentration (see Fig. 14), and 4-12mM range of manganese concentration (see Fig. 15).

More preferably, for the enzymatic reaction of the RNase H optimum temperature is 37°C, optimum pH is 7.9, optimum NaCl concentration is 40mM, magnesium ion is 4mM and manganese ion is 8mM.

And the present invention provides uses of the HBV polymerase and the RNase H enzyme derived from the HBV polymerase for screening antiviral agents.

In order to select HBV inhibitors working at the multiplication stage of HBV by using the HBV polymerase, (a) the HBV polymerase is reacted with homopolymer template, radioactive nucleotide and antiviral agent, (b) the reaction solution of (a) stage is adsorpted onto anion adsorption filter and dried, (c) the radioactivity of the adsorbent filter is measured by using scintillation cocktail and,

(d) the results of (c) stage is compared with those of comparative sample which does not contain a antiviral agent in the reaction mixture and used to calculate the inhibitory effects of HBV multiplication.

5

Then poly(dA) / oligo(dT)₁₂₋₁₈ is used as homopolymer template for DDDP activity and poly(rA) / oligo(dT)₁₂₋₁₈ for RDDP activity preferably and DE-81 anion adsorbent filter is used preferably.

10

In addition, in order to select antiviral agents by using the RNase H enzyme derived from the HBV polymerase, at first, enzyme substrates should be prepared by the process described below and then the radioactivity of the substrate should be measured.

15

In order to select HBV inhibitors working at the multiplication stage of HBV by using the RNase H domain of the HBV polymerase,

(a) the RNase H enzyme is reacted with the reaction substrate and antiviral agent,

20

(b) ammonium acetate is added to stop the reaction of (a) stage and precipitated by adding ethanol and centrifuging,

(c) the radioactivity of the supernatant of the precipitate is measured and,

25

(d) the results of (c) stage is compared with those of

comparative sample which does not contain an antiviral agent in the reaction mixture and used to calculate the inhibitory effects of HBV multiplication.

5 Practical and presently preferred embodiments of the present invention are illustrative as shown in the following Examples.

 However, it will be appreciated that those skilled in the art, on consideration of this disclosure, may make
10 modification and improvements within the spirit and scope of the present invention.

Examples

15 <Example 1> Construction of the expression vector pMPH

 In order to construct the expression vector pMPH, the nucleotide sequence of 6 histidine residues was inserted into the 3'-terminus of HBV polymerase gene of the expression vector pMPLX already established (Korean
20 Patent Application 94-3918) by site-specific insertion mutagenesis.

 The *E. coli* CJ 236 strain (ung⁻, dut⁻) was transformed by the expression vector pMPLX, cultured until OD₆₀₀ was 0.3, and then infected with M13 K07 helper
25 phage. After 1 hour, kanamycin was added into the growing culture and after culturing overnight, DNA

containing uracil was obtained . The mutant expression vector containing 6 histidine residues, (His)₆ tag, was constructed by performing *in vitro* DNA polymerization, which used the primer for mutagenesis having nucleotide
5 sequence of SEQ ID. NO: 1 (see Sequence Listing) and the above single-stranded DNA according to the Kunkel's method (Kunkel, T. A., Proc. Natl. Acad. Sci., 82 : 488, 1985). The mutant expression vector described above was selected by using the restriction enzyme *EcoRI* site
10 inserted and DNA sequence analysis.

Particularly, the primer for mutagenesis was prepared to have 6 histidine codons directly upstream of the stop codon in the open reading frame of HBV polymerase gene. Thus the histidine tag was inserted without any sequence
15 change in HBV polymerase gene. In addition, the *EcoRI* site (GAATTC) which lacked in the expression vector pMPLX was introduced directly downstream of the stop codon, thus the mutant expression vector and the transformant can be easily selected. The mutant expression vector can
20 be have the right open reading frame and expression direction, which is examined by the analysis of DNA sequence.

As a result, the expression vector pMPH of the present invention which can produce the recombinant
25 protein, the HBV polymerase fused with MBP and histidine tag was constructed (see Fig.1).

<Example 2> Expression of the HBV polymerase

In order to obtain a large amount of HBV polymerase, *E. coli* NM 522 strain was transformed with the expression vector pMPH which can produce the recombinant protein, the HBV polymerase fused with MBP and histidine tag.

The transformant described above was inoculated into 3 ml of 2X YT medium, cultured for 16-20 hours and the growing culture was diluted 1 : 100 and again inoculated into 400 ml of LB medium. Then the growing culture was incubated at 37°C until OD₆₀₀ reached 0.5, isopropylthiogalactoside (IPTG) was added into the *E. coli* culture and again cultured at 20-37°C for 6 - 18 hours.

<Example 3> Purification of the HBV polymerase

In order to purify the HBV polymerase, the *E. coli* culture which was induced for the expression in Example 2 was centrifuged for 20 minutes at 4,000 rpm. The cell pellet was resuspended in 5 ml of buffer A (10 mM Tris-Cl, pH 7.4, 200 mM NaCl, 1 mM EDTA) and disrupted by sonication for 20 seconds 5 times. To separate the HBV polymerase by using MBP, the crude extract was centrifuged and the supernatant was loaded into amylose resin column (New England Biolab.) of which the resin was washed with buffer A, 50 times volume of the supernatant volume. The HBV polymerase fused with MBP was eluted by using buffer A containing 10 mM maltose.

In addition, in order to purify HBV polymerase highly by using the histidine tag, the protein fraction obtained above as again loaded into Ni²⁺-NTA resin (QIAGEN). After the loaded protein sample passed the column, buffer
5 B with 10 times volume of the resin volume (50 mM Na₂HPO₄, 300 mM NaCl, 10 % glycerol, 10 mM imidazole, pH 6.0) containing 10 mM imidazole was used to wash the column and then buffer B with 30 times volume of the resin volume is used to wash the column. The HBV
10 polymerase was eluted and purified by using 10-200 mM concentration gradient of imidazole.

<Example 4> Identification of molecular weight and purity of the HBV polymerase

15 In order to identify molecular weight and purity of the HBV polymerase which was obtained in Example 3, the purified HBV polymerase was electrophoresed on SDS-polyacrylamide gel according to the Laemmli's method and western blotting was also performed, and the amount
20 of HBV polymerase was quantified according to Bradford's method.

The ^{MRGS}His-Ag which can bind histidine-tagged protein was used for western blot analysis. The ^{MRGS}His-Ag (QIAGEN) which was diluted at the ratio of 1 : 2,000 was
25 used as a first antigen and the rabbit anti-mouse IgG (Sigma) at the ratio of 1 : 16,000 was used as a second

antigen.

As a result, HBV polymerase of the present invention containing a histidine tag was identified to have 144 KD protein size onto SDS-polyacrylamide gel, which was not
5 detected in the case of the HBV polymerase already purified due to hydrolysis of the protein (see Fig.2). The expressed protein concentration was 400 $\mu\text{g/l}$, which was similar to already purified HBV polymerase.

10 <Example 5> Identification of the HBV polymerase activity

In order to identify the activity of the recombinant HBV polymerase purified in the above process, the recombinant HBV polymerase was electrophoresed on the
15 7.5% SDS-polyacrylamide gel containing substrate (4.5% stacking gel). After the electrophoresis, the gel was soaked in renaturation buffer solution (50 mM Tris-Cl, pH 7.4) and incubated at 4°C for 24 hours with shaking.

The renaturated gel by removing SDS was mixed with 100 ml of reaction solution (50 mM Tris-Cl, pH 7.4, 5 mM
20 dithiotreitol, 5 mM MgCl_2 , 0.01% NP-40, 10 mM dGTP, 10 mM dATP, 10 mM dCTP, 20 μCi ^{32}P -dTTP) and the reaction mixture was incubated at 37°C for 16 hours. Then 500 ml 5% of TCA-1% $\text{Na}_4\text{P}_2\text{O}_7$ was added into the reaction mixture described above and the gel was washed at 4°C for 20
25 hours and the dried gel was exposed onto X-ray film.

As a result, the 144 KD protein which is putative HBV

polymerase fused with MBP and histidine tag showed reverse transcriptase activity. In addition, the reverse transcriptase activity of the HBV polymerase with histidine tag is more active than HBV polymerase without histidine tag.

<Example 6> Assay of the HBV polymerase activity

In order to assay the activity of HBV polymerase purified at above process, the reaction mixture containing 0.5 μ g the purified HBV polymerase, standard polymerase reaction buffer, 50 ng homopolymer template, and 2 μ Ci 32 P-d TTP (~ 3000 Ci/mmol) was incubated at 37°C for 1hour. The poly(dA)/oligo (dT)₁₂₋₁₈ was used as a template in the assay of the DDDP activity and the poly (rA)/ oligo (dT)₁₂₋₁₈ was used as a template in the assay of the RDDP activity. This reaction mixture was adsorbed onto a disk filter and the disk filter was washed and mixed with scintillation cocktail (5.5g/l PPO, 0.15g/l POPOP) to measure the radioactivity of 32 P- dTTP by using liquid scintillation counter.

As a result, the HBV polymerase containing a histidine tag of the present invention showed relatively higher specific activity (cpm/ μ g) of DDDP and RDDP than the activity of the polymerase already purified. Particularly, the DDDP activity of the recombinant HBV polymerase produced by the expression vector of the

present invention was 19 times higher than the already purified polymerase and the RDDP activity of the recombinant HBV polymerase produced by expression vector of the present invention was 5.6 times higher than the already purified polymerase (see Table 1).

<Table 1> Comparison of the enzyme activity of recombinant HBV polymerase

		pMPLX	pMPH	
		amylose column	amylose column	Ni-NTA column
DDDP	C.P.M.	12,757	44,134	239,850
	specific activity	1	3.4	18.8
RDDP	C.P.M.	11,689	32,713	65,935
	specific activity	1	2.79	5.64

<Example 7> Constuction of the expression vector pMPRL

In order to construct the expression vector pMPRL which produces RNase H enzyme derived from HBV polymerase, the gene fraction of the 3'-terminus HBV polymerase gene encoding RNase H domain (subdomain) was amplified by PCR. The 5'-terminal primer has the sequence of SEQ ID. NO: 2 and 3'-terminal primer has the sequence of SEQ ID. NO: 3 (see Sequence Listing). The expression vector pMPLX (Korean Patent Application

94-3918) was used as a DNA template. The size of the DNA fraction amplified was identified to be 0.5 kb. The above DNA fraction was cut by *XmnI* restriction enzyme site and ligated with the plasmid pMAL-c2. The ligation product was cut by restriction enzyme *EcoRI*, so the DNA fraction which corresponds to RNase H enzyme was separated. The above DNA fraction was ligated with the plasmid pMAL-c2 cut with *EcoRI* restriction enzyme, and finally the expression vector pMPRL of 7.2kb size was constructed (see Fig.3). The open reading frame of MBP gene of the plasmid pMAL-c2 and the RNase H gene was connected correctly, which was identified by the sequence analysis of the ligated *EcoRI* site.

15 <Example 8> Construction of the expression vector pMRH

In order to construct the expression vector pMRH which produces RNase H domain derived from HBV polymerase containing a histidine tag, the expression vector pMPH which produces HBV polymerase containing a histidine tag was used. The expression vector pMPH was cut by restriction enzyme *BamHI* and *HindIII*, so the DNA fraction which contains DNA sequence encoding a histidine tag was obtained. After the expression vector pMPRL which was constructed in Example 7 to produce RNase H enzyme, was cut by restriction enzyme *BamHI* and *HindIII*, the DNA sequence encoding a histidine tag was inserted

into the above expression vector pMPRH. As a result, the expression vector pMRH was constructed which produces the recombinant protein, the RNase H domain fused with MBP and histidine tag at the C-terminus (see Fig.4).

5

<Example 9> Expression of the RNase H domain derived from human HBV polymerase

RNase H domain derived from HBV polymerase was expressed in *E. coli* by using the expression vector pMPRL and pMRH. *E. coli* NM 522 was transformed by the
10 expression vector pMRH and pMPRL respectively and the transformants were cultured overnight in 2X YT medium, overnight. This growing cultures were diluted 1 : 100, inoculated into a glucose rich medium and incubated until
15 OD₆₀₀ reached 0.5. And then IPTG was added into the medium of which the final concentration was 0.5 mM. The above growing cultures were incubated again at 23°C for 12 hours and the RNase H domain was expressed.

The above cultured broth was centrifuged for 10
20 minutes at 3,000 rpm and the cell pellet was washed with 10 ml of column buffer (10 mM Tris-Cl, pH 7.4, 200 mM NaCl, 1 mM EDTA), centrifuged again and resuspended. The cells were freezed and thawed 4 times repeatedly, and then disrupted by sonication for 10 seconds 3 times. The
25 crude extract prepared in the above process was centrifuged for 30 minutes at 13,000 rpm, 4°C and the

supernatant was separated. The above process was repeated 3 times and then the supernatant passed the amylose resin. The column was washed by using column buffer with 50 times of resin volume, and the RNase H domain was eluted by using buffer containing 10 mM maltose. The purified recombinant protein was hydrolyzed into MBP and the RNase H domain by treating protease factor Xa.

In addition, the RNase H domain produced from the expression vector pMRH of the present invention was purified by using histidine tag affinity column, because RNase H has a histidine tag at the C-terminus. The resin (Ni-NTA, QIAGEN) used in the the histidine tag affinity column was activated by using sonication buffer (50 mM sodium phosphate, pH 8.0, 300 mM sodium chloride) and 4-5 ml of the activated resin charged the glass tube whose diameter was about 1 cm. The protein sample obtained from above description passed the resin at the 0.1 ml/min flow rate and the column was washed by using washing buffer with the 100-200 times volume of protein sample (50 mM sodium phosphate, pH 6.0, 300 mM sodium chloride, 10% glycerol). The recombinant protein was eluted by washing the column with concentration gradient of 0.01-0.5 M imidazole.

As a result, the active RNase H domain was separated from the histidine tag affinity column at 50 mM

concentration of imidazole. The purified RNase H domain derived from human HBV polymerase was identified by performing SDS-PAGE and western blotting (see Fig. 5 and Fig.6).

5

<Example 10> Preparation of the substrate of the RNase H enzyme

In order to identify the RNase H activity of the present invention, RNA / DNA complex which can be used as
10 a substrate of the RNase H enzyme was prepared by performing in vitro transcription with T7 RNA polymerase. The template used in the preparation of run-off transcript was the plasmid pBS-oligo derived from the plasmid pBS. *E. coli* was transformed with the plasmid
15 pBS-oligo, and the transformant was cultured massively to obtain large amount of the plasmid pBS-oligo by using the alkaline lysis method. The restriction enzyme *Sma*I site is located in the 102 nucleotides downstream of T7 promoter of the plasmid pBS-oligo.

20 The plasmid pBS-oligo was cut with restriction enzyme *Sma*I, electrophoresed on 0.7% agarose gel, eluted from the gel, and used to perform in vitro transcription. The in vitro transcription was performed by using the reaction mixture which is composed of 30 μ l distilled
25 water, 20 μ l 5X reaction buffer (200 mM Tris-Cl, pH 7.5, 30 mM magnesium chloride, 10 mM spermidine, 50 mM sodium

chloride), 10 μ l dithiotreitol, 10 μ l solution containing 2-5 μ g the plasmid pBS-oligo cut with restriction enzyme *Sma*I, 5 μ l 2.5 mM ATP, 5 μ l 2.5 mM GTP, 5 μ l 2.5 mM UTP, 5 μ l 0.1 mM CTP, 3 μ l RNasin, 5 μ l [32 P] CTP 50 μ Ci, 2 μ l T7 RNA polymerase. The total reaction volume was adjusted 100 μ l, and the above reaction mixture was incubated for 1-2 hours at 37°C. Then the RNA produced which is 102 nucleotides long was separated by using QIAquick nucleotide removal kit (QIAGEN), electrophoresed with 1.5 μ l on 8 M urea-6% TBE gel, and then the gel was dried, exposed onto X-ray film for more than 48 hours. The X-ray film was developed to examine the radioactive signal.

The 102 nucleotides RNA whose radioactive signal was identified was mixed with the same mole of synthetic DNA oligomer (43-mer) which has DNA sequence of SEQ ID. NO: 4, heated at 70-80°C, for 3-10 minutes, and then cooled at room temperature. Finally RNA / DNA complex which had radioactive signal was prepared by above process whose structure of RNA / DNA complex is shown in Fig. 7.

<Example 11> Identification of the RNase H activity

The RNase H activity was identified by using the RNase H enzyme purified in Example 9 and RNA / DNA complex with radioactive signal prepared in Example 10. In order to identify the RNase H activity of the present

invention, 1 μ g of RNase H enzyme of the present invention was mixed with 40 mM Tris-Cl (pH 7.9), 4 mM magnesium chloride, 40 mM potassium chloride and RNA / DNA complex, and the above reaction mixture was incubated
5 at 37°C for 3 hours, and then the reaction was stopped by adding 50 mM EDTA to the reaction mixture. To the small volume of the reaction solution the same amount of 10% ice-cold TCA was added. The above reaction mixture was incubated at 4°C for 1 hour and centrifuged for 15
10 minutes at 4°C, 13,000 rpm. The supernatant was obtained and the radioactive signal of the 20 μ l of supernatant was measured by using scintillation cocktail.

As a control, MBP which was fused with the RNase H domain was reacted in the same condition, but the
15 radioactive signal was not detected. In addition, the activity of the RNase H activities of the following proteins was compared in the same condition with one another, and the following proteins consisted in crude extract obtained from Example 9, the commercially
20 available reverse transcriptase of the Moloney murine Leukemia Virus, RNase H enzyme purified by amylose column after expression from the expression vector pMPRL, RNase H enzyme purified primarily by amylose column and secondarily by histidine tag affinity column after
25 expression from the expression vector pMRH. As a result, the activity of RNase H domain was 90% of the activity of

RNase H which consists in the commercially available reverse transcriptase of the Moloney murine Leukemia Virus (see Fig. 8).

5 **<Example 12> Variation of the RNase H activity according to the amount of RNase H enzyme**

In order to measure the variation of the RNase H activity according to the reaction condition, the reaction condition of the RNase H enzyme was changed and
10 the activity of the RNase H enzyme was measured. In detail, as the amount changed from 0 to 1.6 μ g, the RNase H enzyme of the present invention was mixed with 40 mM Tris-Cl (pH 7.9), 4 mM magnesium chloride, 40 mM potassium chloride, and 30,000 cpm RNA / DNA complex and
15 the reaction mixture was incubated at 37°C for 3 hours. As a result, the RNase H enzyme activity became higher, as the amount of the enzyme increases (see Fig.9).

20 **<Example 13> Variation of the RNase H activity according to the reaction period**

1 μ g of the RNase H enzyme was mixed with 40 mM Tris-Cl (pH 7.9), 4 mM magnesium chloride, 40 mM potassium chloride and 30,000 cpm RNA / DNA complex, and
25 the reaction mixture was incubated at 37°C as described in Example 11, and the reaction period showing the enzyme activity sufficiently was measured. It took about 3

hours for the RNase H enzyme to be active (see Fig. 10).

**<Example 14> Variation of the RNase H activity according
to the reaction temperature**

5 As the temperature was varied from 0 to 52°C, 1 µg
of the RNase H enzyme was mixed with 40 mM Tris-Cl (pH
7.9), 4 mM magnesium chloride, 40 mM potassium chloride,
and 30,000 cpm RNA / DNA complex, and the reaction
mixture was incubated for 3 hours as described in Example
10 11.

As a result, the RNase H activity was identified
at relatively broad range of 32-42°C (see Fig.11).

15 **<Example 15> Variation of the RNase H activity to the pH
of the reaction solution**

As the pH was changed from pH 6.0 to pH 10.0, 1 µg of
RNase H enzyme was mixed with 40 mM Tris-Cl, 4 mM
magnesium chloride, 40 mM potassium chloride and 30,000
cpm RNA / DNA complex and the reaction mixture was
20 incubated at 37°C for 3 hours, as described in Example
11. The RNase H activity had the highest value at the pH
range of 7.5 -8.8 (see Fig. 12).

25 **<Example 16> Variation of the RNase H activity according
to the concentration of potassium chloride**

As the concentration of potassium chloride was

changed from 0 to 400 mM, 1 μ g of RNase H enzyme was mixed with 40 mM Tris-Cl (pH 7.9), 4 mM magnesium chloride and 30,000 cpm RNA / DNA complex and the reaction mixture was incubated at 37°C for 3 hours as described in Example 11. The RNase H activity had the highest value when the concentration of potassium chloride was 20-100 mM (see Fig. 13).

10 **<Example 17> Variation of the RNase H activity according to the concentration of magnesium ion**

As the concentration of magnesium ion (Mg^{2+}) was changed from 0 to 50 mM, 1 μ g of RNase H enzyme was mixed with 40 mM Tris-Cl (pH 7.9), 40 mM potassium chloride and 30,000 cpm RNA / DNA complex and the reaction mixture was incubated at 37°C, for 3 hours, as described in Example 11. The RNase H activity had the highest value when the concentration of magnesium ion was 4 to 8 mM (see Fig. 14).

20 **<Example 18> Variation of the RNase H activity according to the concentration of manganese ion**

As the cation (II) of the reaction solution was substituted with manganese ion (Mn^{2+}), 1 μ g of RNase H enzyme was mixed with 40 mM Tris-Cl (pH 7.9), 40 mM potassium chloride and 30,000 cpm RNA / DNA complex and the reaction mixture was incubated at 37°C for 3 hours,

as described in Example 11. The RNase H activity had the highest value when the concentration of manganese ion is 4 to 12 mM (see Fig. 15).

5 <Example 19> Screening of HBV antiviral agents using HBV
polymerase

By using the HBV polymerase of the present invention, the following reaction was performed in order to screen antiviral agents. 50 μ l of the reaction mixture
10 consisting in 0.5 μ g of the purified HBV polymerase, 50 mM Tris-Cl, pH 7.4, 50 mM potassium chloride, 0.5 mM manganese chloride, 1 mM dithiothreitol, 0.01% NP-40, 50 ng homopolymer template (RDDP : poly (rA)/oligo (dT)₁₂₋₁₈ ; DDDP : poly (dA)/oligo (dT)₁₂₋₁₈) and 2 μ Ci [α -³²P] TTP
15 (3,000 Ci/mmol) respectively was incubated at 37°C for 1 hour. Then, the reaction solution was precipitated by TCA and adsorbed onto DE-81 anion adsorbent filter. The adsorbent filter containing the sample was washed with 0.1 M phosphate buffer, and the washed filter was dried
20 with infrared rays. Then after mixing with scintillation cocktail the RNase H activity was assayed by measuring radioactivity (cpm).

In order to select the antiviral agents by using the above process, 10 μ l of putative antiviral agents was
25 added into the above reaction mixture, and the antiviral activity was measured and compared with the enzyme

activity of the reaction sample which didn't contain antiviral agents.

**<Example 20> Screening of HBV antiviral agents using the
RNase H enzyme**

5

By using the RNase H enzyme of the present invention, a enzyme substrate was prepared by the following process in order to screen antiviral agents.

In order to prepare RNA transcript, single-stranded
10 DNA of M13 phage was purified and transcribed by *E. coli* RNA polymerase. The following reaction mixture of 4 μ l buffer solution (200 mM Tris-Cl, pH 7.5, 30 mM magnesium chloride, 10 mM spermidine and 50 mM sodium chloride), 2 μ l 100 mM dithiothreitol, 1 μ l RNasin (Promega), 1 μ l 2.5
15 mM ATP, 1 μ l 2.5 mM GTP, 1 μ l 2.5 mM UTP, 0.6 μ l distilled water without RNase, 2.4 μ l 0.1 mM CTP, 1 μ l single-stranded DNA of M13mp19 (about 1 μ g/ μ l) and 5 μ l [α -³²P] CTP (10 μ Ci/ μ l, Amersham) were incubated at 37°C
20 for 15 hours with 1 μ l of *E. coli* RNA polymerase (Promaga). The above reaction mixture passed Sephadex G-50 column so as to remove the nucleic acids remained. The volume of reaction solution which passed the above column was measured and 0.5 X volume of 7.5 M ammonium acetate and 2 X volume of ethanol were added into the
25 above reaction mixture and precipitated at -20°C for 1 hour. The RNA transcript precipitated above was obtained

by centrifuging and washing with 70% ethanol. Then RNA transcript was resuspended in 100 μ l of 10mM Tris-Cl, pH 8.0 and the radioactive signal of 1 μ l of RNA transcript solution was measured.

5 In addition, RNA transcript which was obtained by the above process and single-stranded DNA of M13mp19 suspended in buffer solution (10 mM Tris-Cl, pH 8.0, 1mM EDTA, 80 mM potassium chloride) were heated in same amounts at 85°C for 2 minutes, and then the above
10 reaction mixture was cooled at room temperature. As a result, RNA / DNA complex was obtained by precipitating with ethanol and suspended in 100 μ l of TE buffer (pH 8.0).

15 In order to measure the above RNase H activity, 50 μ l of the reaction mixture consisting in 25 μ l of 2X buffer solution (40 mM Tris-Cl, pH 8.0, 20 mM potassium chloride, 2 mM magnesium chloride, 4 mM dithiothreitol), 5 μ l RNase H domain, 5 μ l enzyme substrate (about 50,000
20 cpm) and 15 μ l distilled water was prepared and incubated at 37°C for 30 minutes. The reaction was stopped by using 25 μ l of 7.5 M ammonium acetate and precipitated by using 230 μ l of ethanol. In order to measure antiviral activities, 5 μ l of antiviral agents was added to the
25 above reaction mixture and the antiviral activity was measured and compared with the enzyme activity of RNase

H of the reaction sample which didn't contain antiviral agents.

As illustrated in the above description, highly
5 active HBV polymerase can be produced massively in *E. coli* because HBV polymerase of the present invention is stable due to its histidine tag. And HBV polymerase of the present invention can be easily purified by using histidine tag affinity column chromatography. Precisely,
10 the HBV polymerase shows highly specific activity such as 5-20 times higher activity than the polymerase already purified since it can be purified doubly by exploiting MBP and histidine tag. And the RNase H enzyme derived from HBV polymerase can be also produced massively in *E. coli*, and purified easily. Furthermore, the RNase H
15 activity is maintained highly during the purification process.

Therefore, the HBV polymerase and its RNase H domain of the present invention can be used to select various
20 antiviral agents effectively. And the antiviral agents which is selected by the screening methods of the present invention can be used to understand the mechanism of HBV replication and to treat hepatitis, liver cirrhosis, and liver cancer caused by HBV infection.

25

SEQUENCE LISTING

(1) GENERAL INFORMATION

(iii) NUMBER OF SEQUENCES : 4

5

(2) INFORMATION FOR SEQ ID. NO: 1:

(i) SEQUENCE CHARACTERISTICS :

(A) LENGTH : 50 base pairs

(B) TYPE : nucleic acid

10 (C) STRANDEDNESS : single

(D) TOPOLOGY : linear

(ii) MOLECULAR TYPE : DNA (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION : SEQ ID. NO: 1 :

15 GGAGACCACC GCATCACCAT CACCATCACT GAGAATTCAC GCCCATCAGG

20

25

(2) INFORMATION FOR SEQ ID. NO: 2 :

(i) SEQUENCE CHARACTERISTICS :

(A) LENGTH : 35 base pairs

(B) TYPE : nucleic acid

5 (C) STRANDEDNESS : single

(D) TOPOLOGY : linear

(ii) MOLECULAR TYPE : DNA (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION : SEQ ID. NO: 2

10 CCCC GTTGCC CGGGAATTCC GAACAGGTCT CTGCC

15

20

25

(3) INFORMATION FOR SEQ ID. NO: 3 :

(i) SEQUENCE CHARACTERISTICS :

(A) LENGTH : 18 base pairs

(B) TYPE : nucleic acid

5 (C) STRANDENESS : single

(D) TOPOLOGY : linear

(ii) MOLECULAR TYPE : DNA (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION : SEQ ID. NO: 3:

10 TCACGGTGGT CTCCATGC

15

20

25

(4) INFORMATION FOR SEQ ID. NO: 4 :

(i) SEQUENCE CHARACTERISTICS :

(A) LENGTH : 43 base pairs

(B) TYPE : nucleic acid

5 (C) STRANDEDNESS : single

(D) TOPOLOGY : linear

(ii) MOLECULAR TYPE : DNA (synthetic oligonucleotide)

(iii) SEQUENCE DESCRIPTION : SEQ ID. NO: 4:

10 AATTGCGTGC GAGGCGATTG GTTTGGGGCC AGAGTGGGCC AGG

15

20

What is Claimed is

1. A HBV polymerase containing a histidine tag.
- 5 2. The HBV polymerase according to claim 1, which is fused with maltose binding protein.
3. The HBV polymerase according to claim 2, which contains a histidine tag at the C-terminus.
- 10 4. A expression vector which produces the HBV polymerase of claim 1 in *Escherichia coli*.
5. The expression vector according to claim 4, which is the expression vector pMPH.
- 15 6. A *E. coli* transformant which is prepared by transforming host cells with the expression vector of claim 4.
- 20 7. The *E. coli* transformant according to claim 6, which is prepared by transforming host cells with the expression vector pMPH (KCCM-10084).
- 25 8. A process for preparing the HBV polymerase of claim 1, comprising steps as follows : (a) culturing the *E.*

coli transformants of claim 6, (b) inducing the expression of the HBV polymerase, (c) performing histidine tag affinity column chromatography with crude extract of the *E. coli* transformant.

5

9. The process for preparing the HBV polymerase according to claim 8, comprising further steps as follows : (a) performing amylose affinity column chromatography, (b) treating with protease factor Xa.

10

10. A RNase H enzyme derived from human HBV polymerase.

11. The RNase H enzyme according to claim 10, which is fused with maltose binding protein.

15

12. The RNase H enzyme according to claim 11, which contains a histidine tag at the C-terminus.

20

13. The RNase H enzyme according to claim 10, which is active at 32-42°C, at the pH range of 7.5-8.8, in reaction solution containing potassium chloride 20-100 mM, magnesium ion 4-8 mM or manganese ion 4-12 mM.

25

14. The expression vector pMPRL which produces the RNase H enzyme of claim 11.

15. The *E. coli* transformant which is prepared by transforming host cells with the expression vector pMPRL of claim 14 (KCCM-10092).
- 5
16. The expression vector pMRH which produces the RNase H enzyme of claim 12.
17. The *E. coli* transformant which is prepared by transforming host cells with the expression vector pMRH of claim 16 (KCCM-10091).
- 10
18. A process for preparing the RNase H enzyme of claim 10, comprising steps as follows : (a) inducing the expression of the RNase H enzyme after culturing the *E. coli* transformants of claim 15 or claim 17, (b) performing amylose affinity column chromatography with crude extract, (c) treating protease factor Xa
- 15
19. The process for preparing RNase H enzyme of claim 10 according to claim 18, comprising a further step : performing histidine tag affinity column chromatography in the *E. coli* transformant of claim 17.
- 20
20. A use of HBV polymerase of claim 1 for screening
- 25

antiviral agents of human HBV.

21. A use of the RNase H enzyme of claim 10 for
screening inhibitors of the RNase H enzyme and
5 antiviral agents of human HBV.
22. A method for screening antiviral agents, comprising
steps as follows :
- 10 (a) reacting the HBV polymerase of claim 1 with
radioactive nucleotides and antiviral agent,
(b) adsorbing the reaction solution onto anion
adsorbent filter, and drying the filter,
(c) measuring the radioactivity of the adsorption
filter of (b) stage by using scintillation cocktail,
15 (d) comparing the results of (c) with that of
comparative sample reacted without antiviral agents
of (a).
23. A method for screening antiviral agents, comprising
20 steps as follows :
- (a) reacting the RNase H enzyme of claim 10 with
RNA / DNA complex and antiviral agent,
(b) adding ammonium acetate to stop the reaction of
(a) stage, and precipitating with ethanol and
25 centrifuging,
(c) measuring the radioactivity of the supernatant

of (b) stage,
(d) comparing the results of (c) stage with that of
comparative sample reacted without antiviral agents
of (a) stage.

5

10

15

20

25

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6





Fig. 7




Fig. 8

Comparison of enzyme activity




Fig. 9




Fig. 10




Fig. 11




Fig. 12




Fig. 13




Fig. 14





Fig. 15



BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

To
DONG WHA PHARM. IND CO.LTD.
5, SOONWHA-DONG,
JOONG-KU,
SEOUL,
Korea

RECEIPT IN THE CASE OF AN ORIGINAL
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR :	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY
Escherichia coli NM522/pMPH	KCCM-10084
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by:	
<input type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on July.10.1996 (date of the original deposit)	
IV. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Korean Culture Center of Microorganisms	Signature(s) of person(s) having the power to represent the International Depositary Authority of of authorized official(s)
Address: Department of Food Engineering; College of Eng. Yonsei University Sodaemun-gu, Seoul 120-749 Korea	Date: July, 19, 1996

1 Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired : where a deposit made outside the Budapest Treaty after the acquisition of the status of international depositary authority is converted into a deposit under the Budapest Treaty, such date is the date on which the microorganism was received by the international depositary authority

Form BP/4 (KCCM Form 17)

Sole page

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

To
DONG WHA PHARM. IND. CO., LTD.
5, Soonwha-dong, Joong-ku,
SEOUL, KOREA

RECEIPT IN THE CASE OF AN ORIGINAL
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: Escherichia coli NME22/pMRH	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: KCCM-10091
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: <input type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on Nov. 2, 1996 (date of the original deposit) ¹	
IV. INTERNATIONAL DEPOSITARY AUTHORITY	
Name : Korean Culture Center of Microorganisms Address : Department of Food Engineering College of Eng. Yonsei University Sodaemun-gu, Seoul 120-749 Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s) Date : Nov 11, 1996

¹ Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired; where a deposit made outside the Budapest Treaty after the acquisition of the status of international depositary authority is converted into a deposit under the Budapest Treaty, such date is the date on which the microorganism was received by the international depositary authority.

Form BP/4 (KCCM Form 17)

Side page

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

To
DONG WHA PHARM. IND. CO., LTD.
5, Soonwha-dong, Joong-ku,
SEOUL, KOREA

RECEIPT IN THE CASE OF AN ORIGINAL
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR :	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY
Escherichia coli NM522/pMPRL	KCCM-10092
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by:	
<input type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on Nov. 25, 1996 (date of the original deposit) ¹	
IV. INTERNATIONAL DEPOSITARY AUTHORITY	
Name : Korean Culture Center of Microorganisms	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s)
Address : Department of Food Engineering College of Eng. Yonsei University Sodaemun-gu, Seoul 120-749 Korea	Date: Nov. 29, 1996

¹ Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired, where a deposit made outside the Budapest Treaty after the acquisition of the status of international depositary authority is converted into a deposit under the Budapest Treaty, such date is the date on which the microorganism was received by the international depositary authority

Form BP/4 (KCCM Form 17)

Seal Page

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 97/00152

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶: C 12 N 15/52, 1/21, 15/55 // (C 12 N 1/21; C 12 R 1:19)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁶: C 12 N 15/52, 1/21, 15/55

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPIL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96/10 649 A1 (SOUTH-WEST FOUNDATION FOR BIOMEDICAL RESEARCH) 11 April 1996 (11.04.96), abstract. -----	1



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

04 November 1997 (04.11.97)

Date of mailing of the international search report

12 November 1997 (12.11.97)

Name and mailing address of the ISA/AT
AUSTRIAN PATENT OFFICE
Kohlmarkt 8-10
A-1014 Vienna
Facsimile No. 1/53424/535

Authorized officer

Wolf

Telephone No. 1/53424/436

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/KR 97/00152

Im Recherchenbericht angeführtes Patentedokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WO A1 9610649	11-04-96	keine - none - rien	